Find Grants

3/17/16 → 3/17/18

Project: Research project

Vossoughi - Rapid Impact Grants to Address the Research Needs of the Chicago Public Schools

Vossoughi, S.

Arie and Ida Crown Memorial

12/1/18 → 5/31/21

Project: Research project

Vossoughi - Seed Funding to Address the Research Agenda of the Chicago Public Schools

Vossoughi, S.

Spencer Foundation

6/1/19 → 8/31/21

Project: Research project

VPF - IL Coalition for the Fair Sentencing of Children (JWLOP)

Biehl, J. L.

Vital Projects Fund, Inc.

3/2/15 → 8/31/16

Project: Research project

Vu, Thanh Huyen VA Proposal

Vu, T. H. T.

Edward Hines, Jr. VA Hospital

9/1/22 → 8/31/23

Project: Research project

Vulnerability to Drug Use & HIV: Advancing Prevention for Rural African Americans

Miller, G., Chen, E. & Chen, E.

University of Georgia, National Institute on Drug Abuse

7/1/14 → 6/30/20

Project: Research project

VX09-809-102 Cohort 3: Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX809 Alone and in Combination with VX-770

McColley, S. A.

Vertex Pharmaceuticals Incorporated

9/1/12 → 8/31/13

Project: Research project

VX09-809-102 COHORT 4: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaft

McColley, S. A.

Vertex Pharmaceuticals Incorporated

10/14/13 → 10/14/15

Project: Research project

VX12-770-112: A Phase 3, TWO-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation

McColley, S. A.

Vertex Pharmaceuticals Incorporated

9/1/12 → 8/31/13

Project: Research project

VX12-770-115: An Ocular Safety Study of Kalydeco? Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

McColley, S. A.

Vertex Pharmaceuticals Incorporated

5/31/13 → 5/31/15

Project: Research project

VX12-809-103: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosi

McColley, S. A.

Vertex Pharmaceuticals Incorporated

5/29/13 → 5/29/15

Project: Research project

VX12-809-105: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygo

McColley, S. A.

Vertex Pharmaceuticals Incorporated

12/10/13 → 12/31/16

Project: Research project

VX14-661-106: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis,

McColley, S. A.

Vertex Pharmaceuticals Incorporated

4/14/15 → 4/15/18

Project: Research project

VX14 809-109: A Phase 3, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygou

McColley, S. A.

Vertex Pharmaceuticals Incorporated

3/26/15 → 3/26/18

Project: Research project

VX15-770-124: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have

McColley, S. A.

Vertex Pharmaceuticals Incorporated

3/1/16 → 7/31/18

Project: Research project

VX15-770-126: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have

McColley, S. A.

Vertex Pharmaceuticals Incorporated

9/11/17 → 12/31/20

Project: Research project

VX15-809-110: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508de

McColley, S. A.

Vertex Pharmaceuticals Incorporated

10/1/15 → 1/18/19

Project: Research project

VX15-809-115: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 through 5 Years With Cystic Fibrosis, Homozygous for the F508del CFTR

McColley, S. A.

Vertex Pharmaceuticals Incorporated

11/1/16 → 11/1/18

Project: Research project

VX16-809-116: A Phase 3, Rollover Study to Evaluate the Safety of Long term Treatment with Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutati

McColley, S. A.

Vertex Pharmaceuticals Incorporated

6/12/17 → 12/31/19

Project: Research project

VX16-809-116: A Phase 3, Rollover Study to Evaluate the Safety of Long term Treatment with Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutati

McColley, S. A.

Vertex Pharmaceuticals Incorporated

6/12/17 → 7/3/19

Project: Research project

VX16-809-122: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age with Cystic Fibrosis, Homozygous for F508del

McColley, S. A.

Vertex Pharmaceuticals Incorporated

8/21/18 → 8/20/21

Project: Research project

VX16-809-122: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age with Cystic Fibrosis, Homozygous for F508del

McColley, S. A.

Vertex Pharmaceuticals Incorporated

8/21/18 → 8/20/21

Project: Research project

VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal F

McColley, S. A.

Vertex Pharmaceuticals Incorporated

7/10/18 → 7/17/20

Project: Research project

VX17-445-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation.

McColley, S. A.

Vertex Pharmaceuticals Incorporated

12/17/18 → 8/31/50

Project: Research project

VX18-445-106-Part B: A Phase 3, Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age

McColley, S. A.

Vertex Pharmaceuticals Incorporated

8/9/19 → 8/31/50

Project: Research project

Filters for Grants

Vortioxetine as a Potential Enhancer of Cognition in Schizophrenia

Vossoughi - Rapid Impact Grants to Address the Research Needs of the Chicago Public Schools

Vossoughi - Seed Funding to Address the Research Agenda of the Chicago Public Schools

VPF - IL Coalition for the Fair Sentencing of Children (JWLOP)

Vu, Thanh Huyen VA Proposal

Vulnerability to Drug Use & HIV: Advancing Prevention for Rural African Americans

VX09-809-102 Cohort 3: Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX809 Alone and in Combination with VX-770

VX09-809-102 COHORT 4: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaft

VX12-770-112: A Phase 3, TWO-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation

VX12-770-115: An Ocular Safety Study of Kalydeco? Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

VX12-809-103: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosi

VX12-809-105: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygo

VX14-661-106: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis,

VX14 809-109: A Phase 3, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygou

VX15-770-124: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have

VX15-770-126: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have

VX15-809-110: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508de

VX15-809-115: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 through 5 Years With Cystic Fibrosis, Homozygous for the F508del CFTR

VX16-809-116: A Phase 3, Rollover Study to Evaluate the Safety of Long term Treatment with Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutati

VX16-809-116: A Phase 3, Rollover Study to Evaluate the Safety of Long term Treatment with Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutati

VX16-809-122: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age with Cystic Fibrosis, Homozygous for F508del

VX16-809-122: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age with Cystic Fibrosis, Homozygous for F508del

VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal F

VX17-445-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation.

VX18-445-106-Part B: A Phase 3, Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Find Grants

Filters for Grants

Search results